Therapeutic | Tosatoxumab |
Target | Toxin A |
Heavy Chain | EVQMVQSGAEVKKPGEPLKISCKGSGYKFGTHWIGWVRQRPGKGLEWMGIIHPADSETKYSPSFQGQVSFSADKSSNTAYLHWSTLRASDTAMYYCARRSGSSSWYALDFWGQGTMVTVSS |
Light Chain | QSVLTQSPSASGTPGQRVTISCSGGSSNIGSNTVNWYQQFPGAAPKLLIYTNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCATWDDSLNGLYVFGTGTKVTVL |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2013 |
INN Year Recommended | 2014 |
Companies Involved | Aridis Pharmaceuticals, Kenta Biotech |
Conditions Approved | na |
Conditions Active | Nosocomial pneumonia |
Conditions Discontinued | Sepsis |
Notes |